NCT01272193 - Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

296

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec/insulin aspart

Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).

DRUG

insulin glargine

Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.

Trial Locations (50)

070 0002

Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido

253 0052

Novo Nordisk Investigational Site, Chigasaki-shi, Kanagawa

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

103 0027

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

243 0432

Novo Nordisk Investigational Site, Ebina-shi

815 8555

Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka

358 0003

Novo Nordisk Investigational Site, Iruma-shi, Saitama

598 0048

Novo Nordisk Investigational Site, Izumisano

247 0056

Novo Nordisk Investigational Site, Kamakura-shi

221 0802

Novo Nordisk Investigational Site, Kanagawa-shi, Yokohama

277 0825

Novo Nordisk Investigational Site, Kashiwa-shi, Chiba

582 0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

125 0054

Novo Nordisk Investigational Site, Katsushika-ku, Tokyo

350 0851

Novo Nordisk Investigational Site, Kawagoe-shi, Saitama

800 0252

Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka

963 8851

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

861 8045

Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto

862 0976

Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto

830 8577

Novo Nordisk Investigational Site, Kurume-shi, Fukuoka

839 0863

Novo Nordisk Investigational Site, Kurume-shi, Fukuoka

615 8125

Novo Nordisk Investigational Site, Kyoto-shi, Kyoto

399 0006

Novo Nordisk Investigational Site, Matsumoto-shi, Nagano

880 0034

Novo Nordisk Investigational Site, Miyazaki

900 0032

Novo Nordisk Investigational Site, Naha

311 0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

662 0971

Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo

080 0016

Novo Nordisk Investigational Site, Obihiro-shi, Hokkaido

080 0848

Novo Nordisk Investigational Site, Obihiro-shi, Hokkaido

355 0321

Novo Nordisk Investigational Site, Ogawa

831 0016

Novo Nordisk Investigational Site, Okawa-shi, Fukuoka

144 0035

Novo Nordisk Investigational Site, Ota-ku, Tokyo

323 0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

870 0039

Novo Nordisk Investigational Site, Ōita

060 0033

Novo Nordisk Investigational Site, Sapporo, Hokkaido

060 0062

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

060-0001

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

062 0007

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

060 8648

Novo Nordisk Investigational Site, Sappro-shi, Hokkaido

857 1165

Novo Nordisk Investigational Site, Sasebo-shi, Nagasaki

980 0021

Novo Nordisk Investigational Site, Sendai

329 0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi

424 0853

Novo Nordisk Investigational Site, Shizuoka

985 0852

Novo Nordisk Investigational Site, Tagajō-shi

825 8567

Novo Nordisk Investigational Site, Tagawa-shi, Fukuoka

569 1096

Novo Nordisk Investigational Site, Takatsuki-shi, Osaka

865 0064

Novo Nordisk Investigational Site, Tamana-shi, Kumamoto

167 0043

Novo Nordisk Investigational Site, Tokyo

300 0832

Novo Nordisk Investigational Site, Tsuchiura-shi, Ibaraki

901 2104

Novo Nordisk Investigational Site, Urasoe-shi,

227 0054

Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa